Výsledky vyhledávání - "Michelle Brooker-McEldowney"

Flavopiridol in Chronic Lymphocytic Leukemia

Autor: James T. Dalton, John C. Byrd, Thomas S. Lin, Mitch A. Phelps, Michael R. Grever, Beth Christian, Mollie E. Moran, Beth Fischer, Leslie A. Andritsos, Michelle Brooker-McEldowney, Kristie A. Blum, A. Dimitrios Colevas

Publikováno v: Clinical Leukemia. 1:292-297

Whereas chronic lymphocytic leukemia (CLL) responds to therapy, patients invariably experience relapse, and many patients with advanced disease acquire mutation or deletion of the p53 gene, resulting in resistance to most standard therapies. Alemtuzu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3801c0ece177073a7230abc7b49e214
https://doi.org/10.3816/clk.2007.n.020

Zobrazit plný text záznamu

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Autor: Katherine L. Farley, Larry J. Schaaf, Sarah M. Mitchell, Amy J. Johnson, Mitch A. Phelps, James T. Dalton, Eunju Hurh, David Jarjoura, Thomas S. Lin, Michael R. Grever, Beth Fischer, Nyla A. Heerema, Darlene M. Rozewski, Kristie A. Blum, Mollie E. Moran, Di Wu, Michelle Brooker-McEldowney, John C. Byrd

Publikováno v: Blood. 113(12)

We previously reported interim results of a phase 1 trial in patients with chronic lymphocytic leukemia (CLL) whereby flavopiridol was administered intravenously as a 30-minute bolus followed by 4-hour infusion. We now report full pharmacokinetic (PK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39559a0a8db9cbebd503f3db2e8fb4da
https://pubmed.ncbi.nlm.nih.gov/18981292

Zobrazit plný text záznamu

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Publikováno v: Blood. 109(2)

Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a7966e62e90616f23ddba1181ee61a
https://pubmed.ncbi.nlm.nih.gov/17003373

Zobrazit plný text záznamu

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule

Autor: John C. Byrd, Kristie A. Blum, Michael R. Grever, Beth Fischer, Mollie E. Moran, Sara Broering, Thomas S. Lin, Michelle Brooker-McEldowney

Publikováno v: Blood. 106:2124-2124

Introduction: Flavopiridol, a synthetic flavone with marked clinical efficacy in refractory high risk CLL, can cause overwhelming TLS with hyperkalemia. Accrual to a National Cancer Institute (NCI) sponsored phase 1 trial of flavopiridol (NCI 5746) w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d1fc6110862dd4526581b5930cba22f
https://doi.org/10.1182/blood.v106.11.2124.2124

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání